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ABSTRACT
Eleven elderly patients (older than 65 years) with relapsed large cell lymphoma were treated with high-dose
myeloablative therapy and autologous peripheral blood progenitor cell support (ABMT). All 11 patients were
in sensitive relapse at the time of ABMT. Treatment-related mortality was 9%. Median CD34 cell collection
was 4.8  106 cells/kg. Median time to hematologic recovery was 11 days for granulocytes (range, 9 to 16 days)
and 18 days for platelets (range, 14 to 42 days). Nine of 11 patients (81%) achieved a complete response
following ABMT. Median time to treatment failure was 17 months. The 4-year disease-free and overall survival
is projected to be 44%. When compared with a cohort of patients under age 65 years with sensitive relapsed
large cell lymphoma treated with ABMT during the same time interval, disease-free and overall survival are
comparable. ABMT is feasible, tolerable, and effective in elderly patients with relapsed large cell lymphoma
with disease-free survival rates comparable to younger patients.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
High-dose myeloablative chemoradiotherapy or
chemotherapy with autologous hematopoietic pro-
genitor cell support (ABMT) is potentially curative for
patients with intermediate-grade or high-grade non-
Hodgkin’s lymphoma who are either induction fail-
ures or who relapse after initial chemotherapy. How-
ever, most published series [1-3] have restricted this
procedure to patients less than 60 years of age because
of the potential poor tolerance of older patients to this
procedure. More recent studies [4-10] have reported
the outcome of this approach in patients over the age
of 60 years with acceptable toxicities. These published
studies [4-10] have reported on a total of 159 patients
over the age of 60 years who were treated with
ABMT. Of these 159 patients, 134 patients had re-
lapsed or refractory lymphoma treated with ABMT.
Among these 134 patients with lymphoma treated
with ABMT, at least 16 were older than 65 years.
Thus, the database in the elderly (65 years or older) is
limited. The purpose of this communication is to
report the outcomes of our series of consecutive pa-
tients over the age of 65 years with relapsed malignant
lymphoma, diffuse large cell type (LCL), and to ex-
pand the existing database in the elderly.
PATIENTS AND METHODS
Between January 1, 1995 and June 1, 2002, we
treated 11 consecutive patients 65 years of age or older
with relapsed B-cell LCL with high-dose myeloabla-
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tive chemoradiotherapy or chemotherapy with autol-
ogous peripheral blood progenitor cell support
(PBPC) at our institution (Lutheran General Hospi-
tal, Cancer Care Center, Park Ridge, IL). These 11
patients were screened and selected from a cohort of
57 patients over the age of 65 years with relapsed LCL
during this time period. The 46 patients who did not
undergo high-dose myeloablative chemotherapy or
chemoradiotherapy were excluded for the following
reasons: poor performance status (18 patients), failure
to achieve a response to salvage chemotherapy (13
patients), patient refusal (8 patients), and failure to
meet criteria for high-dose myeloablative therapy (7
patients). Patient characteristics at the time of high-
dose myeloablative therapy with PBPC support are
shown in Table 1. The international prognostic index
for all 11 patients at presentation and at relapse was
low-intermediate. The prior chemotherapy regimens
included cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) (9 patients); cyclophospha-
mide, mitoxantrone, vincristine, prednisone (CNOP);
and methotrexate, bleomycin, doxorubicin, cyclo-
phosphamide, vincristine, dexamethasone (mBACOD)
(1 patient each). All 11 patients relapsed from a com-
plete response (CR) to prior chemotherapy. All 11
patients met criteria for myeloablative therapy as pre-
viously published [11], and were in sensitive relapse
before high-dose myeloablative therapy. The salvage
regimens used to induce (at the very least) a partial
response included: ifosfamide, carboplatin, etoposide
(ICE; 5 patients) [12]; mesna, ifosfamide, mitox-
antrone, etoposide (MINE; 2 patients) [13]; dexa-
methasone, high-dose cytarabine, and cisplatin
(DHAP; 2 patients) [14]; and etoposide, methylpred-
nisolone, cytarabine, and cisplatin (ESHAP; 2 pa-
tients) [15]. The number of cycles of salvage therapy
administered was 2 to 3. At the conclusion of salvage
therapy before PBPC mobilization there were 2 pa-
tients in CR and 9 patients in partial response.
Informed consent for both PBPC mobilization
and high-dose myeloablative therapy was obtained in
all 11 patients before proceeding with PBPC mobili-
zation. The informed consent allowed for patient data
collection.
Apheresis, Peripheral Blood Progenitor Cell
Mobilization and Collection
Subsequent to the documentation of either CR or
partial response to salvage therapy, all patients under-
went placement of a VasCath (Bard, Salt Lake City,
UT) or Neostar (Horizon, Manchester, GA) catheter
in the superior vena cava and underwent PBPC mo-
bilization by using high-dose cyclophosphamide 4
g/m2 intravenously day 1 and etoposide 200 mg/m2
intravenous piggyback (IVPB) days 1, 2, and 3, with
ﬁligrastim 10 g/kg starting on day 4. The apheresis
procedure was carried out by methods previously de-
scribed [11]. The apheresis procedure commenced
when the peripheral blood CD34 count was close to
or exceeded 20 cells/L. The procedure was com-
pleted when a minimum of 2  106 CD34 cells/kg
were collected.
Conditioning Regimens (High-Dose Myeloablative
Therapy)
All patients were admitted to the inpatient unit to
receive high-dose myeloablative therapy. The condi-
tioning regimens used consisted of fractionated total
body irradiation (TBI) 1.2 Gy twice daily on days 8
to 5, etoposide 60 mg/kg intravenously/or syringe
pump on day 4, and cyclophosphamide 100 mg/kg
IVPB on day 2 in the ﬁrst 6 patients [16]. In an
attempt to ameliorate the toxicities from TBI, the
BEAM regimen (carmustine 300 mg/m2 intravenously
on day 6, etoposide 200 mg/m2 IVPB over 2 hours
(daily for 4 doses) on days 5 to 2, cytarabine 200
mg/m2 IVPB over 60 minutes every 12 hours for 8
doses on days 5 to 2, and melphalan 140 mg/m2
IVPB over 15 minutes on day 1) was used in the last
5 patients [17].
Supportive Care
Following completion of the conditioning regi-
men, all patients received the collected and cyropre-
served PBPC product on day 0. Prophylactic antibi-
otics were started on day 1 and consisted of oral
valacyclovir 500g every 12 hours, oral ciproﬂoxacin
500 mg every 12 hours, oral cephalexin 500 mg every
6 hours, and oral ﬂuconazole 400 mg daily. Prophy-
lactic antibiotics were continued until hematologic
recovery or until the onset of febrile neutropenia, at
which point they were discontinued. At the onset of
febrile neutropenia, patients were pan-cultured and
intravenous broad-spectrum antibiotics were started
that included cefepime  vancomycin, (and, on occa-
Table 1. Patient Characteristics
Patient
No. Sex/Age Therapy
Initial
Response
Time to
Relapse (mo)
1 M/66 mBACOD CR 66
2 M/66 CHOP CR 15
3 F/66 CHOP CR 46
4 F/66 CHOP CR 23
5 F/65 CHOP CR 24
6 F/71 CHOP CR 15
7 M/65 CHOP CR 18
8 F/71 CHOP CR 18
9 M/78 CNOP CR 15
10 M/76 CHOP CR 18
11 M/72 CHOP CR 64
Abbreviations: mBACOD, methotrexate, bleomycin, doxorubi-
cin, cyclophosphamide, vincristine, and dexamethasone; CHOP,
cyclophosphamide, doxorubicin, vincristine, and prednisone; CR,
complete response.
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sion amphotericin B); ﬁlgrastim 5 g/kg subcutaneous
was started on day 0 and continued until the absolute
neutrophil count (ANC) exceeded 1500 cells/L for 3
consecutive days, at which point ﬁlgrastim was discon-
tinued. Irradiated, leukocyte-depleted packed red
blood cells were transfused in patients when the he-
moglobin fell to less than 8 g/dL in patients without
any history of underlying heart disease. The threshold
for red cell transfusion was 9 g/dL in patients with a
history of heart disease. Single-donor leukocyte-de-
pleted platelet packs were transfused when the platelet
count fell to less than 10 000 cells/L; in patients with
active bleeding, single-donor platelets packs were used
to maintain a platelet count of 50 000 cells/L. Pa-
tients were placed on a low-bacteria diet and total
parenteral nutrition was instituted if caloric intake fell
to less than 1000 calories per day. Patients were en-
couraged to ambulate and exercise in their rooms
using either a treadmill or exercise bicycles for at least
a total of 30 minutes per day [18].
Toxicity Grading of the Conditioning Regimen
Toxicities were graded according to the National
Cancer Institute–Bone Marrow Transplantation tox-
icity scores.
Discharge Criteria and Follow-Up
Patients were discharged when the following cri-
teria were met: (1) ANC 1500 cells/L for 3 con-
secutive days; (2) platelets 20 000 cells/L; (3) oral
caloric intake1000 calories per day; and (4) ability to
provide self-care.
Once discharged, patients were followed in the
ambulatory setting. Response to ABMT was deter-
mined at about day 100 by repeat computed tomog-
raphy of the chest, abdomen, and pelvis, and more
recently by computed tomography and positron emis-
sion tomography scans. Patients were seen for fol-
low-up once every 2 months for the ﬁrst year follow-
ing day 100, then once every 3 months for the next 24
months, then once every 6 months until 60 months.
During those visits, a history and physical examination
was conducted along with a complete blood count and
comprehensive metabolic panel.
Follow-up computed tomography and positron
emission tomography scans were performed routinely
once every 6 months for the ﬁrst 36 months and yearly
thereafter unless symptoms or physical signs suggest-
ing recurrent LCL developed, at which time restaging
was carried out.
Survival, Disease-Free Survival, and Comparison
to Patients <60 Years
Disease-free survival was measured from day 0
until relapse or death. Survival was measured from day
0 until death from any cause. The survival and disease-
free survival of these 11 patients was compared with a
cohort of patients under age 65 years treated during
the same time period. These were patients with sen-
sitive-relapse LCL treated with TBI, etoposide, and
cyclophosphamide [16] or the BEAM regimen [17] in
those patients who had received prior radiotherapy.
This cohort consisted of 78 patients (45 men, 33
women). Of these 78 patients, 55 received TBI, eto-
poside, and cyclophosphamide and 23 received BEAM.
RESULTS
Median PBPC collection was 4.6  106 CD34
cells/kg (range, 2.5 to 10  106 cells/kg). The median
number of apheresis performed to yield this collection
was 2 (range, 1-4). The results are shown in Table 2.
Median time to hematologic recovery (ANC 500
cells/L) was 11 days for granulocytes and 18 days for
platelets (platelets  20 000 cells/L). There was 1
patient who died within the ﬁrst 100 days; patient
number 1 (Table 2) was a 65-year-old man who died
from a hemophilus inﬂuenza pneumonia that precip-
Table 2. ABMT Outcomes
Patient
No.
Conditioning
Regimen
Day ANC
> 500
Day Platelets
> 20,000 Response DFS (yrs) Survival (yrs)
1 Cy/TBI/VP 16 30 NE 0.15 0.15
2 Cy/TBI/VP 12 14 CR 6.0* 6.0*
3 Cy/TBI/VP 11 17 CR 5.5* 5.5*
4 Cy/TBI/VP 16 28 NR 0.5 0.5
5 Cy/TBI/VP 11 18 CR 1.25 3.0
6 Cy/TBI/VP 10 12 CR 2.0* 2.0*
7 BEAM 9 17 CR 2.3* 2.3*
8 BEAM 12 19 CR 1.0* 1.0*
9 BEAM 10 18 CR 0.5 0.5
10 BEAM 12 42 CR 0.5 0.5
11 BEAM 11 18 CR 0.5* 0.5*
Abbreviations: DFS, disease-free survival; Cy, cyclophosphamide; TBI, total body irradiation; VP, etoposide; BEAM, carmustine/
etoposide/cytarabine/melphalan; NE, not evaluable; CR, complete response; NR, no response.
*Alive.
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itated adult respiratory distress syndrome and death
on day 45. Thus, the treatment-related mortality
was 9%. The average length of stay was 25 days
(range, 21-54 days). The average in-patient hospital
charge was $39,800 (range, $23,500-115,000).
Of the 11 patients treated, 10 of whom were alive
on day 100, there were 9 CRs and 1 no response.
The CR rate was 81%.
Treatment-related toxicities included: grade 2
mucositis (9 patients), grade 3 mucositis (2 patients,
both of whom received TBI), grade 2 diarrhea (10
patients), grade 3 diarrhea (1 patient who received
TBI). There were 7 episodes of febrile neutropenia.
One patient who received BEAM developed grade 3
proctitis with rectal bleeding and 1 patient developed
atrial ﬁbrillation with a rapid ventricular response and
hypotension. The severest toxicities (grade 3) were
seen most frequently in the 6 patients receiving TBI,
etoposide, and cyclophosphamide.
Currently, 6 patients are alive (as shown in Table
2). The 4 patients who died after day 100 did so from
relapsed LCL. Median disease-free survival is 17
months and the projected disease-free survival at 4
years is 44% (Figure 1). Median survival is 34 months
and the projected survival at 4 years is 44%.
The results of these 11 patients were compared
with those of a cohort of 78 patients under age 65
years treated during the same time period and are
shown in Table 3. At 3 and 4 years the results are
remarkably similar.
DISCUSSION
The treatment of elderly patients with malignant
lymphoma, diffuse, LCL has come under increasing
attention in part because of an aging population and in
part because of the absolute increase in the incidence
of LCL. The use of multidrug chemotherapy, such as
the CHOP regimen, in the elderly can yield long-
term curative results but the toxicities can be substan-
tial when compared with younger patients. In an at-
tempt to improve the cure rate of CHOP alone in the
elderly, a prospective, randomized study was con-
Figure 1. Disease-free survival (DFS) of 11 elderly patients with relapsed LCL treated with high-dose myeloablative therapy and ABMT.
Median disease-free survival is 17 months and the projected 4-year disease-free survival is 44 months.
Table 3. Comparison of Disease-Free Survival, Overall Survival, and 100-day Treatment-Related Mortality for Patients with Sensitive Relapse LCL
Over Age 65 Years to Those Less than 65 Years
Relapse LCL > 65 years, n  11 Relapsed LCL < 65 years, n  78
Year DFS OS TRM DFS OS TRM
1 67% 67% 9% 74% 81% 2.5%
2 44% 67% – 51% 72% –
3 44% 44% – 47% 62% –
4 44% 44% – 47% 53% –
Abbreviations: DFS, disease-free survival; OS, overall survival; TRM, treatment-related mortality.
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ducted that compared rituximab and CHOP with the
standard CHOP regimen. The results of this study
established the superiority of rituximab and CHOP
over CHOP alone in patients older than 60 years of
age [19]. Thus, the treatment of choice in a newly
diagnosed elderly patient with LCL is rituximab and
CHOP.
When elderly patients with LCL relapse, the
treatment approach has typically been to use palliative
measures rather than proceed with potentially curative
ABMT because of the perception than elderly patients
would tolerate the procedure poorly with excessive
morbidity and mortality. The ﬁrst published report on
ABMT in the elderly was by Stamatoullas et al [4]. In
this pilot study, 13 patients over the age of 60 with
relapsed lymphoma were treated with the BEAM reg-
imen and ABMT. There were no treatment-related
deaths, and toxicities were relatively mild (none more
severe than grade 2). The major causes of morbidity
were infections. The subsequent published reports by
Moreau et al. [5], Mazza et al. [6], Jantunen et al. [7],
de la Rubia et al. [8], Gopal et al. [9], and Oliveri et al.
[10] conﬁrmed the pilot study of Stamatoullas et al. [4]
and further demonstrated the ability of elderly pa-
tients to tolerate ABMT. A summary of the aforemen-
tioned published series and the current series are
shown in Table 4. As shown in both Tables 3 and 4,
the results in elderly patients very much parallel the
published results in younger patients; namely, a CR
rate of 60%, a median survival of 1.5 years, and (in our
series) a projected 4-year disease-free survival of 44%.
The toxicities we observed included mucositis, diar-
rhea, proctitis with rectal bleeding, and in 1 patient
atrial ﬁbrillation and hypotension. All these toxicities
were manageable. The 1 treatment-related death oc-
curred as a consequence of hemophilus inﬂuenza
pneumonia and acute respiratory distress syndrome.
In summary, myeloablative therapy and ABMT is
an effective mode of therapy in good performance
status elderly patients with relapsed LCL and should
be considered part of the therapeutic armamentarium.
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